NASDAQ:SVRA - Savara Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Savara Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.75 +0.17 (+6.59 %) (As of 02/19/2020 03:38 PM ET) Add Compare Today's Range$2.55Now: $2.75▼$2.8650-Day Range$2.18MA: $3.19▼$4.9152-Week Range$0.69Now: $2.75▼$11.96Volume27,808 shsAverage Volume406,942 shsMarket Capitalization$113.33 millionP/E RatioN/ADividend YieldN/ABeta1 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SVRA Previous SymbolAMEX:ANX CUSIPN/A CIK1160308 Webhttp://www.savarapharma.com/ Phone512-961-1891Debt Debt-to-Equity Ratio0.23 Current Ratio13.07 Quick Ratio13.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.08 per share Price / Book0.89Profitability EPS (Most Recent Fiscal Year)($1.29) Net Income$-61,520,000.00 Net MarginsN/A Return on Equity-46.13% Return on Assets-33.68%Miscellaneous EmployeesN/A Outstanding Shares41,210,000Market Cap$113.33 million Next Earnings Date3/11/2020 (Estimated) OptionableOptionable Receive SVRA News and Ratings via Email Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SVRA Rates by TradingView Savara (NASDAQ:SVRA) Frequently Asked Questions What is Savara's stock symbol? Savara trades on the NASDAQ under the ticker symbol "SVRA." How were Savara's earnings last quarter? Savara Inc (NASDAQ:SVRA) posted its quarterly earnings results on Thursday, November, 7th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.14. View Savara's Earnings History. When is Savara's next earnings date? Savara is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Savara. What price target have analysts set for SVRA? 6 equities research analysts have issued twelve-month price targets for Savara's shares. Their forecasts range from $1.00 to $17.00. On average, they anticipate Savara's share price to reach $8.60 in the next year. This suggests a possible upside of 212.7% from the stock's current price. View Analyst Price Targets for Savara. What is the consensus analysts' recommendation for Savara? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Savara. What are Wall Street analysts saying about Savara stock? Here are some recent quotes from research analysts about Savara stock: 1. According to Zacks Investment Research, "Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. " (1/21/2020) 2. LADENBURG THALM/SH SH analysts commented, "We believe IMPALA is likely to succeed given GM-CSF’s central role in aPAP, prior trial results and Molgradex’s confirmed low systemic exposure and safety profile. Encouragingly, nearly all eligible patients chose to enroll in the extension trial 26 as of 1Q’19)." (5/10/2019) Has Savara been receiving favorable news coverage? Headlines about SVRA stock have been trending very negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Savara earned a news impact score of -3.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Savara. Are investors shorting Savara? Savara saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,700,000 shares, an increase of 160.9% from the January 15th total of 651,500 shares. Based on an average daily volume of 1,687,700 shares, the days-to-cover ratio is presently 1.0 days. Currently, 6.1% of the shares of the stock are sold short. View Savara's Current Options Chain. Who are some of Savara's key competitors? Some companies that are related to Savara include ProQR Therapeutics (PRQR), Recro Pharma (REPH), Cue Biopharma (CUE), AnaptysBio (ANAB), Avid Bioservices (CDMO), Avedro (AVDR), Calithera Biosciences (CALA), Mallinckrodt (MNK), Progenics Pharmaceuticals (PGNX), Mirum Pharmaceuticals (MIRM), DURECT (DRRX), Verrica Pharmaceuticals (VRCA), Mersana Therapeutics (MRSN), Rigel Pharmaceuticals (RIGL) and Corbus Pharmaceuticals (CRBP). What other stocks do shareholders of Savara own? Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BIOLINERX LTD/S (BLRX), CEL-SCI (CVM), Agile Therapeutics (AGRX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Zynerba Pharmaceuticals (ZYNE), vTv Therapeutics (VTVT), Verastem (VSTM), Geron (GERN) and Gilead Sciences (GILD). Who are Savara's key executives? Savara's management team includes the folowing people: Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)Taneli Jouhikainen, President, Chief Operating Officer (Age 51)David L. Lowrance, Chief Financial Officer (Age 50)Nevan C. Elam, Independent Director (Age 49)Richard J. Hawkins, Independent Director (Age 68)Joseph S. McCracken Ph.D., Independent Director (Age 64)Matthew Pauls J.D., Independent Director (Age 46)Yuri Pikover, Independent Director (Age 56) Who are Savara's major shareholders? Savara's stock is owned by a number of of retail and institutional investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (12.45%), Farallon Capital Management LLC (11.71%), EcoR1 Capital LLC (3.48%), Point72 Asset Management L.P. (2.16%), Jacobs Levy Equity Management Inc. (0.81%) and Renaissance Technologies LLC (0.24%). Company insiders that own Savara stock include David A Ramsay, David L Lowrance, Jaakko Taneli Jouhikainen, Richard J Hawkins, Robert N Neville and Yuri Pikover. View Institutional Ownership Trends for Savara. Which institutional investors are selling Savara stock? SVRA stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp and Bank of America Corp DE. Company insiders that have sold Savara company stock in the last year include David L Lowrance, Jaakko Taneli Jouhikainen and Richard J Hawkins. View Insider Buying and Selling for Savara. Which institutional investors are buying Savara stock? SVRA stock was acquired by a variety of institutional investors in the last quarter, including Bain Capital Life Sciences Investors LLC, EcoR1 Capital LLC, Farallon Capital Management LLC, Point72 Asset Management L.P., Jacobs Levy Equity Management Inc., Renaissance Technologies LLC, Acadian Asset Management LLC and Essex Investment Management Co. LLC. Company insiders that have bought Savara stock in the last two years include David A Ramsay, Robert N Neville and Yuri Pikover. View Insider Buying and Selling for Savara. How do I buy shares of Savara? Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Savara's stock price today? One share of SVRA stock can currently be purchased for approximately $2.75. How big of a company is Savara? Savara has a market capitalization of $113.33 million. The company earns $-61,520,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. View Additional Information About Savara. What is Savara's official website? The official website for Savara is http://www.savarapharma.com/. How can I contact Savara? Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, Austin TX, 78746. The company can be reached via phone at 512-961-1891 or via email at [email protected] MarketBeat Community Rating for Savara (NASDAQ SVRA)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 247 (Vote Outperform)Underperform Votes: 269 (Vote Underperform)Total Votes: 516MarketBeat's community ratings are surveys of what our community members think about Savara and other stocks. Vote "Outperform" if you believe SVRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVRA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2020 by MarketBeat.com StaffFeatured Article: Why does a company issue an IPO?
